ATE361089T1 - Behandlung von neurologischen funktionsstörungen mit fructopyranosesulfamaten und erythropoetin - Google Patents
Behandlung von neurologischen funktionsstörungen mit fructopyranosesulfamaten und erythropoetinInfo
- Publication number
- ATE361089T1 ATE361089T1 AT02724904T AT02724904T ATE361089T1 AT E361089 T1 ATE361089 T1 AT E361089T1 AT 02724904 T AT02724904 T AT 02724904T AT 02724904 T AT02724904 T AT 02724904T AT E361089 T1 ATE361089 T1 AT E361089T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- erythropoetin
- functional disorders
- neurological functional
- fructopyranose sulfamates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26619401P | 2001-02-02 | 2001-02-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE361089T1 true ATE361089T1 (de) | 2007-05-15 |
Family
ID=23013568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02724904T ATE361089T1 (de) | 2001-02-02 | 2002-01-24 | Behandlung von neurologischen funktionsstörungen mit fructopyranosesulfamaten und erythropoetin |
Country Status (17)
Country | Link |
---|---|
US (2) | US6908902B2 (de) |
EP (1) | EP1471871B1 (de) |
JP (1) | JP2005501801A (de) |
KR (1) | KR100896971B1 (de) |
AT (1) | ATE361089T1 (de) |
CA (1) | CA2437333A1 (de) |
CY (1) | CY1106733T1 (de) |
DE (1) | DE60219961T8 (de) |
DK (1) | DK1471871T3 (de) |
ES (1) | ES2284858T3 (de) |
MX (1) | MXPA03006952A (de) |
NO (1) | NO20033440L (de) |
NZ (1) | NZ548578A (de) |
PT (1) | PT1471871E (de) |
RU (1) | RU2317086C2 (de) |
WO (1) | WO2002064085A2 (de) |
ZA (1) | ZA200306818B (de) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080103179A1 (en) * | 2006-10-27 | 2008-05-01 | Tam Peter Y | Combination Therapy |
US7674776B2 (en) | 1999-06-14 | 2010-03-09 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
US20080255093A1 (en) * | 1999-06-14 | 2008-10-16 | Tam Peter Y | Compositions and methods for treating obesity and related disorders |
WO2002064085A2 (en) * | 2001-02-02 | 2002-08-22 | Ortho-Mcneil Pharmaceutical, Inc. | Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin |
WO2003020289A1 (en) * | 2001-08-30 | 2003-03-13 | Ortho-Mcneil Pharmaceutical, Inc. | Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors |
US7439063B2 (en) * | 2002-06-11 | 2008-10-21 | Burnham Institute For Medical Research | Neuroprotective synergy of erythropoietin and insulin-like growth factors |
US20030235576A1 (en) * | 2002-06-15 | 2003-12-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New drug combinations for the treatment of ischaemic conditions |
DE10226814A1 (de) * | 2002-06-15 | 2004-01-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkombinationen zur Behandlung ischämischer Zustände |
EP1815854A1 (de) * | 2002-09-17 | 2007-08-08 | Motac Neuroscience Limited | Behandlung von Dyskinesie |
ATE360415T1 (de) * | 2002-09-17 | 2007-05-15 | Motac Neuroscience Ltd | Behandlung von dyskinesie |
US7388079B2 (en) * | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
AT500929B1 (de) | 2004-11-09 | 2007-03-15 | Medizinische Uni Wien Muw | Pharmazeutische zubereitung die erythropoietin enthält |
JPWO2007020922A1 (ja) * | 2005-08-17 | 2009-02-26 | 創 戸苅 | 脳疾患の治療剤および予防剤 |
US8124095B2 (en) * | 2005-10-07 | 2012-02-28 | Armagen Technologies, Inc. | Fusion proteins for delivery of erythropoietin to the CNS |
US8741260B2 (en) * | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
US8759297B2 (en) * | 2006-08-18 | 2014-06-24 | Armagen Technologies, Inc. | Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns |
US8603980B2 (en) | 2007-01-16 | 2013-12-10 | The Johns Hopkins University | Glutamate receptor antagonists and methods of use |
WO2008137066A1 (en) * | 2007-05-02 | 2008-11-13 | The Board Of Regents Of The University Of Oklahoma | Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases |
AU2008282496B2 (en) | 2007-07-27 | 2013-04-04 | Armagen Technologies, Inc. | Methods and compositions for increasing alpha-iduronidase activity in the CNS |
EA201001814A1 (ru) * | 2008-05-22 | 2011-04-29 | Эдисон Фармасьютикалз, Инк. | Лечение митохондриальных заболеваний миметиками эритропоэтина |
US20090304789A1 (en) * | 2008-06-09 | 2009-12-10 | Thomas Najarian | Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders |
US8580298B2 (en) | 2008-06-09 | 2013-11-12 | Vivus, Inc. | Low dose topiramate/phentermine composition and methods of use thereof |
WO2010108048A2 (en) | 2009-03-18 | 2010-09-23 | Armagen Technologies, Inc. | Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins |
PL2485761T3 (pl) | 2009-10-09 | 2019-10-31 | Armagen Inc | Sposoby i kompozycje do zwiększania aktywności 2-sulfatazy iduronianu w cns |
JP6266529B2 (ja) | 2011-12-02 | 2018-01-24 | アーマジェン・インコーポレイテッドArmagen, Inc. | Cnsにおけるアリールスルファターゼa活性を増加するための方法および組成物 |
CN103316026B (zh) | 2012-03-23 | 2016-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 含芬特明和托吡酯的联合产品及其制备方法 |
US9457008B2 (en) | 2012-03-23 | 2016-10-04 | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China | Joint product comprising synephrine and topiramate |
CN102579367B (zh) | 2012-03-23 | 2014-03-12 | 中国人民解放军军事医学科学院毒物药物研究所 | 托吡酯缓释药物组合物、其制备方法及用途 |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
US10538589B2 (en) | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4513006A (en) | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
US4703008A (en) | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
DK173067B1 (da) | 1986-06-27 | 1999-12-13 | Univ Washington | Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa |
US5242942A (en) | 1992-04-28 | 1993-09-07 | Mcneilab, Inc. | Anticonvulsant fructopyranose cyclic sulfites and sulfates |
US6153407A (en) | 1992-07-28 | 2000-11-28 | Beth Israel Deaconess Medical Center | Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics |
TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
US5384327A (en) | 1992-12-22 | 1995-01-24 | Mcneilab, Inc. | Anticonvulsant sorbopyranose sulfamates |
US5354934A (en) | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
WO1995003034A1 (en) | 1993-07-19 | 1995-02-02 | Amgen Inc. | Stabilization of aerosolized proteins |
US5571787A (en) | 1993-07-30 | 1996-11-05 | Myelos Corporation | Prosaposin as a neurotrophic factor |
US5700909A (en) | 1993-07-30 | 1997-12-23 | The Regents Of The University Of California | Prosaposin and cytokine-derived peptides |
ZA946122B (en) | 1993-08-17 | 1995-03-20 | Amgen Inc | Erythropoietin analogs |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5773569A (en) | 1993-11-19 | 1998-06-30 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
IL116085A (en) | 1994-12-16 | 1999-12-31 | Ortho Pharma Corp | Spray dried erythropoietin |
US5767078A (en) | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
WO1998000124A1 (en) | 1996-06-28 | 1998-01-08 | Ortho Pharmaceutical Corporation | Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration |
US5753694A (en) | 1996-06-28 | 1998-05-19 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS) |
JP4410852B2 (ja) | 1996-08-02 | 2010-02-03 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 単一の共有結合n末端水溶性ポリマーを有するポリペプチド |
JP4541539B2 (ja) | 1997-07-23 | 2010-09-08 | ロシュ ダイアグノスティックス ゲーエムベーハー | 内因性遺伝子活性化によるエリスロポエチンの製造 |
DK0902085T3 (da) | 1997-09-01 | 2004-04-05 | Aventis Pharma Gmbh | Rekombinant human erythropoietin med fordelagtig glycosyleringsprofil |
US6165783A (en) | 1997-10-24 | 2000-12-26 | Neuro Spheres Holdings Ltd. | Erythropoietin-mediated neurogenesis |
DE69933216T2 (de) | 1998-06-15 | 2007-09-20 | GTC Biotherapeutics, Inc., Framingham | Erythropoietin-analog-menschliches serum-albumin fusionsprotein |
WO2000061138A1 (en) * | 1999-04-08 | 2000-10-19 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders |
EA004766B1 (ru) * | 1999-04-13 | 2004-08-26 | Дзе Кеннет С. Уоррен Инститьют, Инк. | Модуляция функции возбуждаемых тканей за счет периферического введения эритропоэтина |
WO2002064085A2 (en) * | 2001-02-02 | 2002-08-22 | Ortho-Mcneil Pharmaceutical, Inc. | Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin |
-
2002
- 2002-01-24 WO PCT/US2002/003096 patent/WO2002064085A2/en active IP Right Grant
- 2002-01-24 RU RU2003124059/14A patent/RU2317086C2/ru not_active IP Right Cessation
- 2002-01-24 AT AT02724904T patent/ATE361089T1/de active
- 2002-01-24 PT PT02724904T patent/PT1471871E/pt unknown
- 2002-01-24 KR KR1020037010232A patent/KR100896971B1/ko not_active IP Right Cessation
- 2002-01-24 ES ES02724904T patent/ES2284858T3/es not_active Expired - Lifetime
- 2002-01-24 DK DK02724904T patent/DK1471871T3/da active
- 2002-01-24 US US10/056,828 patent/US6908902B2/en not_active Expired - Lifetime
- 2002-01-24 NZ NZ548578A patent/NZ548578A/en not_active IP Right Cessation
- 2002-01-24 DE DE60219961T patent/DE60219961T8/de active Active
- 2002-01-24 EP EP02724904A patent/EP1471871B1/de not_active Expired - Lifetime
- 2002-01-24 JP JP2002563882A patent/JP2005501801A/ja not_active Ceased
- 2002-01-24 MX MXPA03006952A patent/MXPA03006952A/es active IP Right Grant
- 2002-01-24 CA CA002437333A patent/CA2437333A1/en not_active Abandoned
-
2003
- 2003-08-01 NO NO20033440A patent/NO20033440L/no not_active Application Discontinuation
- 2003-09-01 ZA ZA2003/06818A patent/ZA200306818B/en unknown
-
2005
- 2005-01-31 US US11/047,420 patent/US20050261182A1/en not_active Abandoned
-
2007
- 2007-07-13 CY CY20071100943T patent/CY1106733T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
KR20040011458A (ko) | 2004-02-05 |
JP2005501801A (ja) | 2005-01-20 |
CY1106733T1 (el) | 2012-05-23 |
RU2317086C2 (ru) | 2008-02-20 |
NO20033440D0 (no) | 2003-08-01 |
US6908902B2 (en) | 2005-06-21 |
NO20033440L (no) | 2003-09-29 |
WO2002064085A3 (en) | 2004-09-10 |
EP1471871B1 (de) | 2007-05-02 |
EP1471871A2 (de) | 2004-11-03 |
CA2437333A1 (en) | 2002-08-22 |
MXPA03006952A (es) | 2004-10-15 |
KR100896971B1 (ko) | 2009-05-14 |
ES2284858T3 (es) | 2007-11-16 |
DK1471871T3 (da) | 2007-09-17 |
PT1471871E (pt) | 2007-06-05 |
US20020169109A1 (en) | 2002-11-14 |
DE60219961T8 (de) | 2008-04-17 |
RU2003124059A (ru) | 2005-01-27 |
EP1471871A4 (de) | 2005-11-09 |
US20050261182A1 (en) | 2005-11-24 |
WO2002064085A2 (en) | 2002-08-22 |
DE60219961D1 (de) | 2007-06-14 |
ZA200306818B (en) | 2005-02-23 |
NZ548578A (en) | 2008-03-28 |
DE60219961T2 (de) | 2008-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60219961T8 (de) | Behandlung von neurologischen funktionsstörungen mit fructopyranosesulfamaten und erythropoetin | |
DE69941586D1 (de) | Verwendung von Uridin in Kombination mit Cholin zur Behandlung von Gedächtnisstörungen | |
HRP20020593B1 (en) | Brain, spinal and nerve injury treatment | |
DE60023873D1 (de) | Mittel zur behandlung von erkrankungen der speiseröhre | |
DE60321929D1 (de) | Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen | |
ATE296634T1 (de) | (s,s)-reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen | |
DK1446387T3 (da) | Substituerede aryl, 1,4-pyrazinderivater | |
DE69936335D1 (de) | Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen | |
DE69927823T2 (de) | Hydrogel für die therapeutische behandlung von aneurysmas | |
ATE286028T1 (de) | Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen | |
DE50214540D1 (de) | Stanz bei der behandlung von wunden | |
MY130489A (en) | Substituted aryl 1, 4-pyrazine derivatives | |
CY1107054T1 (el) | Ενωσεις διτοσυλικου αλατος κιναζολινης | |
ATE381935T1 (de) | Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen | |
DK1287364T3 (da) | Diagnostisk og terapi til makulære degenerationsrelaterede lidelser | |
ATE526020T1 (de) | Gesteigertes kognitives training | |
DE69936285D1 (de) | INDOLOi2,1-BöQUINAZOLIN-6,12-DIONE ANTIMALARIA DERIVATE UND METHODEN ZUR BEHANDLUNG VON MALARIA | |
DE69523654T2 (de) | Verwendung von Ascorbyl-gamma-Linolenat und von Ascorbyl-dihomo-gamma-linolenat zur Behandlung von Asthma, Krebs, kardiovaskulären und inflammatorischen Erkrankungen | |
IL174303A0 (en) | Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders | |
TR200101149T2 (tr) | Dış retina bozukluklarının tedavisi. | |
ATE261724T1 (de) | Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen | |
ATE230741T1 (de) | 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen | |
DE69923464D1 (de) | Benzenesulfonamide derivate in kombination mit beta-blockern zur behandlung von störungen des autonomen nervensystems | |
DE60233740D1 (de) | Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit | |
DE69936779D1 (de) | Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1471871 Country of ref document: EP |